Fulpost 250mg pfs (Fulvestrant PFS) 250mg/5ml

Fulpost 250mg PFS is a prescription injectable containing fulvestrant, used for hormone receptor-positive breast cancer treatment. This single-use prefilled syringe delivers 250mg per 5ml dose for intramuscular use. Store between 2-8°C to maintain potency.

Strength

250mg/5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Adley Formulations

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fulpost 250mg PFS is prescribed for treating hormone receptor-positive metastatic breast cancer in postmenopausal women. It works by blocking estrogen receptors, slowing cancer progression. Patients often ask what fulvestrant is used for, as it targets estrogen-sensitive tumors. The medication is designed for those whose cancer has progressed after hormone therapy.

Side Effects

After administration, fulvestrant gradually reduces estrogen activity in the body, which may lead to temporary changes in menstrual patterns or hot flashes. Some patients report mild injection site reactions like redness or swelling. These effects vary by individual and are typically monitored during treatment.

Precautions & Warnings

Keep Fulpost 250mg PFS refrigerated at 2-8°C and protect from light until use. Do not freeze or shake vigorously. Discard any unused portion as it is for single use only. Inform your healthcare provider about any allergies or bleeding disorders before receiving the injection.

Avoid Interactions

Fulvestrant may interact with blood thinners like warfarin, requiring dose adjustments. Hormonal therapies or supplements should be disclosed to your doctor. Alcohol consumption may amplify certain side effects. CYP3A4 inhibitors could affect fulvestrant levels, so discuss all medications with your physician.

References

Frequently Asked Questions

Fulvestrant is used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women.

It is given as an intramuscular injection in a healthcare setting, typically once monthly.

Always inform your doctor about all medications, including supplements and over-the-counter drugs.

Common effects include injection site reactions, hot flashes, and nausea.

Store between 2-8°C and protect from light until ready for use.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.